Genovis AB
STO:GENO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Genovis AB
Operating Income
Genovis AB
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Genovis AB
STO:GENO
|
Operating Income
kr21.3m
|
CAGR 3-Years
15%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
AddLife AB
STO:ALIF B
|
Operating Income
kr957m
|
CAGR 3-Years
5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
BICO Group AB
STO:BICO
|
Operating Income
-kr249.7m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
|
A
|
AroCell AB (publ)
STO:AROC
|
Operating Income
-kr12m
|
CAGR 3-Years
41%
|
CAGR 5-Years
13%
|
CAGR 10-Years
-5%
|
|
|
Biotage AB
STO:BIOT
|
Operating Income
kr327m
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
16%
|
|
|
MedCap AB (publ)
STO:MCAP
|
Operating Income
kr302.9m
|
CAGR 3-Years
23%
|
CAGR 5-Years
30%
|
CAGR 10-Years
44%
|
|
Genovis AB
Glance View
Genovis AB engages in the research and development of enzyme products. The company is headquartered in Lund, Skane. The company went IPO on 2005-11-11. The firm offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The firm markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.
See Also
What is Genovis AB's Operating Income?
Operating Income
21.3m
SEK
Based on the financial report for Dec 31, 2025, Genovis AB's Operating Income amounts to 21.3m SEK.
What is Genovis AB's Operating Income growth rate?
Operating Income CAGR 5Y
33%
Over the last year, the Operating Income growth was -28%. The average annual Operating Income growth rates for Genovis AB have been 15% over the past three years , 33% over the past five years .
